These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 28915662)
1. Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. Dong Q; Ma Y; Zhang Y; Qu X; Li Z; Qi Y; Liu Y; Li C; Li K; Yang X; Che X Oncotarget; 2017 Aug; 8(34):57163-57173. PubMed ID: 28915662 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094 [TBL] [Abstract][Full Text] [Related]
3. The E3 Ubiquitin Ligase Cbl-b Predicts Favorable Prognosis in Breast Cancer. Liu X; Teng Y; Wu X; Li Z; Bao B; Liu Y; Qu X; Zhang L Front Oncol; 2020; 10():695. PubMed ID: 32435620 [No Abstract] [Full Text] [Related]
4. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients. Sun B; Liu X; Gao Y; Li L; Dong Z Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430 [TBL] [Abstract][Full Text] [Related]
6. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Chen J; Zhao T; Jia S; Zhou S; Zhou L; Wang S; Ding G; Jiang G; Cao L J Cancer; 2018; 9(4):650-659. PubMed ID: 29556322 [No Abstract] [Full Text] [Related]
7. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104 [TBL] [Abstract][Full Text] [Related]
8. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420 [TBL] [Abstract][Full Text] [Related]
9. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
10. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616 [TBL] [Abstract][Full Text] [Related]
11. Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study. Xu D; Wang J; Liu T; Huang Z; Luo J; Chen Y; Lu Y Gland Surg; 2021 Feb; 10(2):770-779. PubMed ID: 33708559 [TBL] [Abstract][Full Text] [Related]
12. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054 [TBL] [Abstract][Full Text] [Related]
13. BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance. Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y Cancer Biomark; 2016; 17(4):437-444. PubMed ID: 27802195 [TBL] [Abstract][Full Text] [Related]
14. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Coppola A; La Vaccara V; Fiore M; Farolfi T; Ramella S; Angeletti S; Coppola R; Caputo D Front Oncol; 2021; 11():690580. PubMed ID: 34123859 [TBL] [Abstract][Full Text] [Related]
15. Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center. Wu Z; Zhao P; Wang Z; Huang X; Wu C; Li M; Wang L; Tian B Front Oncol; 2022; 12():966256. PubMed ID: 35965560 [TBL] [Abstract][Full Text] [Related]
16. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211 [TBL] [Abstract][Full Text] [Related]
17. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability. Shi HJ; Jin C; Fu DL World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110 [TBL] [Abstract][Full Text] [Related]
18. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma. Wang L; Wu H; Wang L; Lu J; Duan H; Liu X; Liang Z Diagn Pathol; 2016 Jul; 11(1):60. PubMed ID: 27391842 [TBL] [Abstract][Full Text] [Related]
19. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma. Dong Q; Zhang Y; Yang XH; Jing W; Zheng LQ; Liu YP; Qu XJ; Li Z Clin Res Hepatol Gastroenterol; 2014 Oct; 38(5):639-48. PubMed ID: 24630955 [TBL] [Abstract][Full Text] [Related]
20. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Distler M; Pilarsky E; Kersting S; Grützmann R Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]